Related Experiment Video
Updated: Nov 10, 2025
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
The Effect of Adding Biological Factors to the Decision-Making Process for Spinal Metastasis of Non-Small Cell Lung
Hyoungmin Kim1, Sam Yeol Chang1, Jongyeon Son1
1Department of Orthopedic Surgery, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul 03080, Korea.
Abstract:
Molecular target therapies have markedly improved the survival of non-small cell lung cancer (NSCLC) patients, especially those with epidermal growth factor receptor (EGFR) mutations. A positive EGFR mutation is even more critical when the chronicity of spinal metastasis is considered. However, most prognostic models that estimate the life expectancy of spinal metastasis patients do not include these biological factors. We retrospectively reviewed 85 consecutive NSCLC patients who underwent palliative surgical treatment for spinal metastases to evaluate the following: (1) the prognostic value of positive EGFR mutation and the chronicity of spinal metastasis, and (2) the clinical significance of adding these two factors to an existing prognostic model, namely the New England Spinal Metastasis Score (NESMS). Among 85 patients, 38 (44.7%) were EGFR mutation-positive. Spinal metastasis presented as the initial manifestation of malignancy in 58 (68.2%) patients. The multivariate Cox proportional hazard model showed that the chronicity of spinal metastasis (hazard ratio (HR) = 1.88, p = 0.015) and EGFR mutation positivity (HR = 2.10, p = 0.002) were significantly associated with postoperative survival. The Uno's C-index and time-dependent AUC 6 months following surgery significantly increased when these factors were added to NESMS (p = 0.004 and p = 0.022, respectively). In conclusion, biological factors provide an additional prognostic value for NSCLC patients with spinal metastasis.
Insights
Epidermal growth factor receptor (EGFR) mutation status and spinal metastasis chronicity significantly impact survival in non-small cell lung cancer (NSCLC) patients undergoing surgery. Incorporating these biological factors improves existing prognostic models for better life expectancy estimation.
Area of Science:
- Oncology
- Molecular Biology
- Surgical Oncology
Background:
- Molecular targeted therapies, particularly those targeting EGFR mutations, have improved survival for non-small cell lung cancer (NSCLC) patients.
- Existing prognostic models for spinal metastasis in NSCLC often lack crucial biological factors like EGFR mutation status and metastasis chronicity.
Purpose of the Study:
- To evaluate the prognostic value of EGFR mutation positivity and spinal metastasis chronicity in NSCLC patients.
- To assess the clinical significance of incorporating these factors into the New England Spinal Metastasis Score (NESMS).
Main Methods:
- Retrospective review of 85 NSCLC patients who underwent palliative surgery for spinal metastases.
- Multivariate Cox proportional hazard model analysis to identify prognostic factors.
- Evaluation of model performance using Uno's C-index and time-dependent AUC.
Main Results:
- 38.2% of patients had EGFR mutations, and 68.2% presented with spinal metastasis as the initial malignancy.
- Both EGFR mutation positivity (HR=2.10, p=0.002) and spinal metastasis chronicity (HR=1.88, p=0.015) were significantly associated with postoperative survival.
- Adding these factors to NESMS significantly improved model accuracy (Uno's C-index p=0.004, AUC p=0.022).
Conclusions:
- EGFR mutation status and spinal metastasis chronicity are significant independent prognostic factors for NSCLC patients with spinal metastases.
- These biological factors enhance the predictive accuracy of existing prognostic models like NESMS.
- Integrating molecular and clinical data offers improved life expectancy estimations for improved patient management.
